Medicine & Life Sciences
Ovarian Neoplasms
100%
Poly(ADP-ribose) Polymerase Inhibitors
43%
Neoplasms
34%
veliparib
32%
Platinum
29%
Ovarian Epithelial Carcinoma
26%
gemcitabine
25%
Paclitaxel
23%
niraparib
21%
Drug Therapy
19%
Survival
16%
tanespimycin
16%
Heterografts
15%
Letrozole
14%
Therapeutics
13%
Somatomedin Receptors
13%
Triple Negative Breast Neoplasms
12%
rucaparib
11%
Homologous Recombination
11%
Progression-Free Survival
11%
Topotecan
11%
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
11%
BMS 536924
10%
OSI 027
10%
Mechanistic Target of Rapamycin Complex 2
10%
Group III Phospholipases A2
10%
AMG 479
10%
Mutation
10%
Carcinoma
10%
Estrogen Receptors
9%
MDX-H210 antibody
9%
Clinical Trials
9%
Nicotinamide N-Methyltransferase
9%
protein kinase C lambda
9%
ribociclib
9%
Fallopian Tubes
9%
Carboplatin
9%
Folate Receptor 1
8%
Puma
8%
Auranofin
8%
TOR Serine-Threonine Kinases
8%
Emergencies
8%
olaparib
8%
Placebos
8%
Epithelioid Hemangioendothelioma
7%
Loratadine
7%
Apoptosis
7%
Bevacizumab
7%
Bispecific Antibodies
7%
pembrolizumab
7%